Kevin Kunzmann

A three-year update of VN for patients with biallelic RPE65 mutation-associated inherited retinal disease improved on the common standard-of-care for retina disease.

Results from the PACORES group clinical trial debunked previously-held beliefs that IVB is unsafe for patients with proliferative diabetic retinopathy undergoing the procedure.

Why substantial evidence is lacking to indicate either therapy method's preference for the treatment of neovascularization.

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

How improvements to patient education, drug costs, and biosimilar therapy availability could keep patients with retina disease away from risky procedures.

Telemedicine screenings provided by a primary care office in an urbanized setting over 2 years showed patients had an 81.9% compliance capture rate—a significant improvement from previous studies in the same field.

Researchers found testing is significantly more practiced by patients offered it in person, versus those referred, with little difference found in mutation identification.

Though cell therapies have gained FDA approval to treat any ocular disease, companies have marketed predominately to patients with AMD, with procedures that could lead to blindness.

Though the 2 dosing regimens had comparable visual acuity improvements over 24 months, patients given ranibizumab once-monthly received treatment nearly 6 more times on average.

Researchers found that, contrary to popular opinion, about 80% of patients are receiving at least 7 dosing regimens of anti-VEGF in their first year of treatment, and that frequency has been proven to improve visual acuity.

SYMTUZA has been approved by the FDA based on the data of a pair of 48-week pivotal phase 3 trials which showed the non-inferiority safety and efficacy of the drug versus a controlled regimen.

Certain lots of the therapy, distributed under the Actavis label in the US, have been detected to have trace amounts of probably human carcinogen NDMA.

The double-blind, placebo-controlled, parallel-group study that aims to observe linaclotide 290 mcg in 600 adult patients with IBS-C in the US.

Positive data for the add-on therapy for patients with type 2 diabetes and chronic kidney disease will be presented at an upcoming medical meeting.

Where does current research focuses its resources, and what may the future of such research involve?

The medical director of the Baylor AT&T Memory Center explains how in-house biomarker testing could improve opportunities for clinical drug research.

The virus was deemed eradicated by the World Health Organization in 1980. But there remains public concern of its use as a bioweapon.

The FDA has approved the first drug indicated for the treatment of smallpox.

The Cleveland Clinic’s pioneer of minority programs plans to end health disparity.

At 48 months, intervention patients significantly fewer incidence rates for CIN3+ versus control patients, with a risk ratio of 0.42.

An analysis of pediatric ICU interactions found that physicians are far more likely to get a beneficial response from families when they show empathy to their emotions.

Targeting metabolism with therapies such as metformin has shown in clinical settings to affect aging itself. In IPF, it could influence the rate of aging as well.

AF is associated with major disease burden, predominately in the form of cardiovascular comorbidities. As a direct oral anti-coagulant, rivaroxaban has been a proven inhibitor of ischemic stroke risks in patients with AF.

Sialorrhea is a common symptom in patients with neurological conditions such as Parkinson’s disease, ALS, cerebral palsy, or in patients who have experienced a stroke.

Military veterans often pursue unique avenues towards a career in civilian health care. Here are the advantages they have, and the challenges they face.

In these new study results, patients administered 300 mg eptinezumab reported 8.2 fewer MMDs from baseline—when mean patient MMDs were 16.1 per month. The rate was significantly improved from that of patients administered placebo.

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

How telehealth-friendly devices could change standard of diabetes care — with the help of physicians, patients, and the overall health care system.

How some of the most recent trial analysis narrows the clinical scope of GLP-1 and SGLT-2 targeting therapies.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.